Download PDF
Semin Thromb Hemost 2024; 50(03): 443-454
DOI: 10.1055/s-0043-1776003
Review Article

In Search of the Perfect Thrombosis and Bleeding-Associated Cancer Scale

Marek Z. Wojtukiewicz
1   Department of Oncology, Medical University of Bialystok, Bialystok, Poland
2   Comprehensive Cancer Center, Bialystok, Poland
,
Petra Tesarova
3   Department of Oncology, Institute of Radiation Oncology, First Faculty of Medicine, Charles University and Bulovka University Hospital, Prague, Czech Republic
,
Debora Karetová
4   Second Department of Medicine—Department of Cardiovascular Medicine, Charles University and General University Hospital, Prague, Czech Republic
,
Jerzy Windyga
5   Department of Hemostasis Disorders and Internal Medicine, Laboratory of Hemostasis and Metabolic Diseases, Institute of Hematology and Transfusion Medicine in Warsaw, Warsaw, Poland
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

Thrombosis and bleeding are commonly observed in cancer patients, and their management is crucial for positive patient outcomes. A comprehensive, prophylactic, and therapeutic management of venous thrombosis should focus on identifying the patients who would benefit most from treatment to reduce mortality and minimize the risk of thrombosis recurrence without significantly increasing the risk of bleeding. Existing cancer scales provide valuable information for assessing the overall burden of cancer and guiding treatment decisions, but their ability to predict thrombotic and bleeding events remains limited. With increasing knowledge of the pathophysiology of cancer and the availability of advanced anticancer therapies, new risk factors for cancer-associated thrombosis and bleeding are being identified. In this report, we analyze the current literature and identify new risk factors for venous thrombosis and bleeding which are not included in routinely used risk scores. While some existing cancer scales partially capture the risk of thrombosis and bleeding, there is a need for more specific and accurate scales tailored to these complications. The development of such scales could improve risk stratification, aid in treatment selection, and enhance patient care. Therefore, further research and development of novel cancer scales focused on thrombosis and bleeding are warranted to optimize patient management and outcomes.

Keywords

thrombosis - venous thrombosis - cancer-associated thrombosis - risk factors - risk assessment - bleeding - risk scale - risk score


Publication History

Article published online:
18 October 2023

© 2023. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Farge D, Frere C, Connors JM. et al; International Initiative on Thrombosis and Cancer (ITAC) advisory panel. 2019 International Clinical Practice Guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol 2019; 20 (10) e566-e581
    CrossrefPubMedGoogle Scholar
  • 2 Elyamany G, Alzahrani AM, Bukhary E. Cancer-associated thrombosis: an overview. Clin Med Insights Oncol 2014; 8: 129-137
    CrossrefPubMedGoogle Scholar
  • 3 Noble S, Pasi J. Epidemiology and pathophysiology of cancer-associated thrombosis. Br J Cancer 2010; 102 (Suppl 1, Suppl 1): S2-S9
    CrossrefPubMedGoogle Scholar
  • 4 De Cicco M. The prothrombotic state in cancer: pathogenic mechanisms. Crit Rev Oncol Hematol 2004; 50 (03) 187-196
    CrossrefPubMedGoogle Scholar
  • 5 Abdol Razak NB, Jones G, Bhandari M, Berndt MC, Metharom P. Cancer-associated thrombosis: an overview of mechanisms, risk factors, and treatment. Cancers (Basel) 2018; 10 (10) 380
    CrossrefPubMedGoogle Scholar
  • 6 Moik F, Englisch C, Pabinger I, Ay C. Risk assessment models of cancer-associated thrombosis—potentials and perspectives. Thromb Update 2021; 5: 100075
    CrossrefPubMedGoogle Scholar
  • 7 Lyman GH, Culakova E, Poniewierski MS, Kuderer NM. Morbidity, mortality and costs associated with venous thromboembolism in hospitalized patients with cancer. Thromb Res 2018; 164 (Suppl. 01) S112-S118
    CrossrefPubMedGoogle Scholar
  • 8 Navi BB, Reiner AS, Kamel H. et al. Risk of arterial thromboembolism in patients with cancer. J Am Coll Cardiol 2017; 70 (08) 926-938
    CrossrefPubMedGoogle Scholar
  • 9 Xiong W. Current status of treatment of cancer-associated venous thromboembolism. Thromb J 2021; 19 (01) 21
    CrossrefPubMedGoogle Scholar
  • 10 Prandoni P, Lensing AW, Piccioli A. et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100 (10) 3484-3488
    CrossrefPubMedGoogle Scholar
  • 11 Angelini DE, Radivoyevitch T, McCrae KR, Khorana AA. Bleeding incidence and risk factors among cancer patients treated with anticoagulation. Am J Hematol 2019; 94 (07) 780-785
    CrossrefPubMedGoogle Scholar
  • 12 Prandoni P, Falanga A, Piccioli A. Cancer and venous thromboembolism. Lancet Oncol 2005; 6 (06) 401-410
    CrossrefPubMedGoogle Scholar
  • 13 Schwarb H, Tsakiris DA. New direct oral anticoagulants (DOAC) and their use today. Dent J 2016; 4 (01) 5
    CrossrefPubMedGoogle Scholar
  • 14 Wojtukiewicz MZ, Skalij P, Tokajuk P. et al. Direct oral anticoagulants in cancer patients. Time for a change in paradigm. Cancers (Basel) 2020; 12 (05) 1144
    CrossrefPubMedGoogle Scholar
  • 15 Khorana AA, Mackman N, Falanga A. et al. Cancer-associated venous thromboembolism. Nat Rev Dis Primers 2022; 8 (01) 11
    CrossrefPubMedGoogle Scholar
  • 16 Khorana AA, Soff GA, Kakkar AK. et al; CASSINI Investigators. Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med 2019; 380 (08) 720-728
    CrossrefPubMedGoogle Scholar
  • 17 Carrier M, Abou-Nassar K, Mallick R. et al; AVERT Investigators. Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med 2019; 380 (08) 711-719
    CrossrefPubMedGoogle Scholar
  • 18 Moik F, Ay C, Pabinger I. Risk prediction for cancer-associated thrombosis in ambulatory patients with cancer: past, present and future. Thromb Res 2020; 191 (Suppl. 01) S3-S11
    CrossrefPubMedGoogle Scholar
  • 19 Thaler J, Ay C, Pabinger I. Venous thromboembolism in cancer patients—risk scores and recent randomised controlled trials. Thromb Haemost 2012; 108 (06) 1042-1048
    PubMedGoogle Scholar
  • 20 Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111 (10) 4902-4907
    CrossrefPubMedGoogle Scholar
  • 21 Łukaszuk RF, Dolna-Michno J, Plens K, Czyżewicz G, Undas A. The comparison between Caprini and Padua VTE risk assessment models for hospitalised cancer patients undergoing chemotherapy at the tertiary oncology department in Poland: is pharmacological thromboprophylaxis overused?. Contemp Oncol (Pozn) 2018; 22 (01) 31-36
    PubMedGoogle Scholar
  • 22 Obi AT, Pannucci CJ, Nackashi A. et al. Validation of the Caprini venous thromboembolism risk assessment model in critically ill surgical patients. JAMA Surg 2015; 150 (10) 941-948
    CrossrefPubMedGoogle Scholar
  • 23 Caprini JA, Arcelus JI, Hasty JH, Tamhane AC, Fabrega F. Clinical assessment of venous thromboembolic risk in surgical patients. Semin Thromb Hemost 1991; 17 (Suppl. 03) 304-312
    PubMedGoogle Scholar
  • 24 Mulder FI, Candeloro M, Kamphuisen PW. et al; CAT-prediction collaborators. The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis. Haematologica 2019; 104 (06) 1277-1287
    CrossrefPubMedGoogle Scholar
  • 25 Cella CA, Knoedler M, Hall M. et al. Validation of the ONKOTEV Risk prediction model for venous thromboembolism in outpatients with cancer. JAMA Netw Open 2023; 6 (02) e230010
    CrossrefPubMedGoogle Scholar
  • 26 Pabinger I, van Es N, Heinze G. et al. A clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts. Lancet Haematol 2018; 5 (07) e289-e298
    CrossrefPubMedGoogle Scholar
  • 27 Noble S. Venous thromboembolism in palliative care patients: what do we know?. Thromb Res 2020; 191 (Suppl. 01) S128-S132
    CrossrefPubMedGoogle Scholar
  • 28 Tchen S, Ryba N, Patel V, Cavanaugh J, Sullivan JB. Validation of bleeding risk prediction scores for patients with major bleeding on direct oral anticoagulants. Ann Pharmacother 2020; 54 (12) 1175-1184
    CrossrefPubMedGoogle Scholar
  • 29 Rosenberg DJ, Press A, Fishbein J. et al. External validation of the IMPROVE bleeding risk assessment model in medical patients. Thromb Haemost 2016; 116 (03) 530-536
    Article in Thieme ConnectPubMedGoogle Scholar
  • 30 Kusaba H, Moriyama S, Hieda M. et al. IMPROVE bleeding score predicts major bleeding in advanced gastrointestinal cancer patients with venous thromboembolism. Jpn J Clin Oncol 2022; 52 (10) 1183-1190
    PubMedGoogle Scholar
  • 31 Lavon O, Tamir T. Evaluation of the Padua Prediction Score ability to predict venous thromboembolism in Israeli non-surgical hospitalized patients using electronic medical records. Sci Rep 2022; 12 (01) 6121
    CrossrefPubMedGoogle Scholar
  • 32 Hayssen H, Cires-Drouet R, Englum B. et al. Systematic review of venous thromboembolism risk categories derived from Caprini score. J Vasc Surg Venous Lymphat Disord 2022; 10 (06) 1401-1409.e7
    CrossrefPubMedGoogle Scholar
  • 33 Roy DC, Wang TF, Mallick R. et al. Growth differentiation factor-15, high-sensitivity cardiac troponin T, and N-terminal pro-B-type natriuretic peptide for predicting risk of venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Thromb Haemost 2022; 122 (07) 1169-1176
    Article in Thieme ConnectPubMedGoogle Scholar
  • 34 Wallentin L, Zethelius B, Berglund L. et al. GDF-15 for prognostication of cardiovascular and cancer morbidity and mortality in men. PLoS One 2013; 8 (12) e78797
    CrossrefPubMedGoogle Scholar
  • 35 Mulder FI, Bosch FTM, Carrier M. et al. Growth differentiation factor-15 for prediction of bleeding in cancer patients. J Thromb Haemost 2022; 20 (01) 138-144
    CrossrefPubMedGoogle Scholar
  • 36 Hiraide M, Shiga T, Minowa Y. et al. Identification of risk factors for venous thromboembolism and evaluation of Khorana venous thromboembolism risk assessment in Japanese lung cancer patients. J Cardiol 2020; 75 (01) 110-114
    CrossrefPubMedGoogle Scholar
  • 37 Obesity JSftSo. Guidelines for the Management of Obesity Disease 2016. Life Science Publishing Tokyo; 2016
    Google Scholar
  • 38 Conteduca V, Wetterskog D, Scarpi E. et al. Plasma tumour DNA as an early indicator of treatment response in metastatic castration-resistant prostate cancer. Br J Cancer 2020; 123 (06) 982-987
    CrossrefPubMedGoogle Scholar
  • 39 Conteduca V, Scarpi E, Wetterskog D. et al. Plasma tumor DNA is associated with increased risk of venous thromboembolism in metastatic castration-resistant cancer patients. Int J Cancer 2022; 150 (07) 1166-1173
    CrossrefPubMedGoogle Scholar
  • 40 Mantha S, Rak J. Cancer genetic alterations and risk of venous thromboembolism. Thromb Res 2022; 213 (Suppl. 01) S29-S34
    CrossrefPubMedGoogle Scholar
  • 41 Yang S, Yang L, Wu Y. et al. Anaplastic lymphoma kinase rearrangement may increase the incidence of venous thromboembolism by increasing tissue factor expression in advanced lung adenocarcinoma. Ann Transl Med 2020; 8 (20) 1307
    CrossrefPubMedGoogle Scholar
  • 42 Al-Samkari H, Leiva O, Dagogo-Jack I. et al. Impact of ALK rearrangement on venous and arterial thrombotic risk in NSCLC. J Thorac Oncol 2020; 15 (09) 1497-1506
    CrossrefPubMedGoogle Scholar
  • 43 Zer A, Moskovitz M, Hwang DM. et al. ALK-rearranged non-small-cell lung cancer is associated with a high rate of venous thromboembolism. Clin Lung Cancer 2017; 18 (02) 156-161
    CrossrefPubMedGoogle Scholar
  • 44 Dou F, Zhang Y, Yi J. et al. Association of ALK rearrangement and risk of venous thromboembolism in patients with non-small cell lung cancer: a prospective cohort study. Thromb Res 2020; 186: 36-41
    CrossrefPubMedGoogle Scholar
  • 45 Corrales-Rodriguez L, Soulières D, Weng X, Tehfe M, Florescu M, Blais N. Mutations in NSCLC and their link with lung cancer-associated thrombosis: a case-control study. Thromb Res 2014; 133 (01) 48-51
    CrossrefPubMedGoogle Scholar
  • 46 Ades S, Kumar S, Alam M. et al. Tumor oncogene (KRAS) status and risk of venous thrombosis in patients with metastatic colorectal cancer. J Thromb Haemost 2015; 13 (06) 998-1003
    CrossrefPubMedGoogle Scholar
  • 47 Serrano E, Saavedra EI, Vico MP. et al. Kras mutation as a risk factor for venous thromboembolism in patients with metastatic pancreatic cancer. J Clin Oncol 2021; 39 (15) e16267-e16267
    CrossrefPubMedGoogle Scholar
  • 48 Chiari R, Ricciuti B, Landi L. et al. ROS1-rearranged non-small-cell lung cancer is associated with a high rate of venous thromboembolism: analysis from a Phase II, Prospective, Multicenter, Two-arms Trial (METROS). Clin Lung Cancer 2020; 21 (01) 15-20
    CrossrefPubMedGoogle Scholar
  • 49 Yi J, Chen H, Li J. et al. The association between ROS1 rearrangement and risk of thromboembolic events in patients with advanced non-small cell lung cancer: a multicenter study in China. Thromb J 2022; 20 (01) 56
    CrossrefPubMedGoogle Scholar
  • 50 Roopkumar J, Poudel SK, Gervaso L. et al. Risk of thromboembolism in patients with ALK- and EGFR-mutant lung cancer: a cohort study. J Thromb Haemost 2021; 19 (03) 822-829
    CrossrefPubMedGoogle Scholar
  • 51 Wang J, Hu B, Li T. et al. The EGFR-rearranged adenocarcinoma is associated with a high rate of venous thromboembolism. Ann Transl Med 2019; 7 (23) 724
    CrossrefPubMedGoogle Scholar
  • 52 Dou F, Li H, Zhu M. et al. Association between oncogenic status and risk of venous thromboembolism in patients with non-small cell lung cancer. Respir Res 2018; 19 (01) 88
    CrossrefPubMedGoogle Scholar
  • 53 Qian X, Fu M, Zheng J, Zhou J, Zhou J. Driver genes associated with the incidence of venous thromboembolism in patients with non-small-cell lung cancer: a systematic review and meta-analysis. Front Oncol 2021; 11: 680191
    CrossrefPubMedGoogle Scholar
  • 54 Vasan SK, Rostgaard K, Majeed A. et al. ABO blood group and risk of thromboembolic and arterial disease: a study of 1.5 million blood donors. Circulation 2016; 133 (15) 1449-1457 , discussion 1457
    CrossrefPubMedGoogle Scholar
  • 55 Englisch C, Moik F, Nopp S, Raderer M, Pabinger I, Ay C. ABO blood group type and risk of venous thromboembolism in patients with cancer. Blood Adv 2022; 6 (24) 6274-6281
    CrossrefPubMedGoogle Scholar
  • 56 Schleef M, Strobel E, Dick A, Frank J, Schramm W, Spannagl M. Relationship between ABO and Secretor genotype with plasma levels of factor VIII and von Willebrand factor in thrombosis patients and control individuals. Br J Haematol 2005; 128 (01) 100-107
    CrossrefPubMedGoogle Scholar
  • 57 Garas SN, McAlpine K, Ross J. et al. Venous thromboembolism risk in patients receiving neoadjuvant chemotherapy for bladder cancer. Urol Oncol 2022; 40 (08) 381.e1-3 -81.e7
    CrossrefPubMedGoogle Scholar
  • 58 Patel SV, Zhang L, Wei XS. et al. A population-based cohort study of venous thromboembolism rates following surgery and during adjuvant chemotherapy in patients with colon cancer. Dis Colon Rectum 2020; 63 (03) 336-345
    CrossrefPubMedGoogle Scholar
  • 59 Di Nisio M, Candeloro M, Rutjes AWS, Porreca E. Venous thromboembolism in cancer patients receiving neoadjuvant chemotherapy: a systematic review and meta-analysis. J Thromb Haemost 2018; 16 (07) 1336-1346
    CrossrefPubMedGoogle Scholar
  • 60 Qi WX, Min DL, Shen Z. et al. Risk of venous thromboembolic events associated with VEGFR-TKIs: a systematic review and meta-analysis. Int J Cancer 2013; 132 (12) 2967-2974
    CrossrefPubMedGoogle Scholar
  • 61 Petrelli F, Cabiddu M, Borgonovo K, Barni S. Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials. Ann Oncol 2012; 23 (07) 1672-1679
    CrossrefPubMedGoogle Scholar
  • 62 Deb S, Boknäs N, Sjöström C, Tharmakulanathan A, Lotfi K, Ramström S. Varying effects of tyrosine kinase inhibitors on platelet function—a need for individualized CML treatment to minimize the risk for hemostatic and thrombotic complications?. Cancer Med 2020; 9 (01) 313-323
    CrossrefPubMedGoogle Scholar
  • 63 Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 2008; 300 (19) 2277-2285
    CrossrefPubMedGoogle Scholar
  • 64 Wojtukiewicz MZ, Rek MM, Karpowicz K. et al. Inhibitors of immune checkpoints-PD-1, PD-L1, CTLA-4-new opportunities for cancer patients and a new challenge for internists and general practitioners. Cancer Metastasis Rev 2021; 40 (03) 949-982
    CrossrefPubMedGoogle Scholar
  • 65 Moik F, Chan WE, Wiedemann S. et al. Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy. Blood 2021; 137 (12) 1669-1678
    CrossrefPubMedGoogle Scholar
  • 66 Icht O, Darzi N, Shimony S. et al. Venous thromboembolism incidence and risk assessment in lung cancer patients treated with immune checkpoint inhibitors. J Thromb Haemost 2021; 19 (05) 1250-1258
    CrossrefPubMedGoogle Scholar
  • 67 Ando Y, Hayashi T, Sugimoto R. et al. Risk factors for cancer-associated thrombosis in patients undergoing treatment with immune checkpoint inhibitors. Invest New Drugs 2020; 38 (04) 1200-1206
    CrossrefPubMedGoogle Scholar
  • 68 Kartolo A, Yeung C, Moffat GT, Hanna L, Hopman W, Baetz T. Venous thromboembolism events in patients with advanced cancer on immune checkpoint inhibitors. Immunotherapy 2022; 14 (01) 23-30
    CrossrefPubMedGoogle Scholar
  • 69 Bjørnhart B, Kristiansen C, Asmussen J. et al. Clinical impact of venous thromboembolism in non-small cell lung cancer patients receiving immunotherapy. Thromb Res 2023; 221: 164-172
    CrossrefPubMedGoogle Scholar
  • 70 Hegde AM, Stroud CRG, Cherry CR, Yogarajah M, Cherukuri SD, Walker PR. Incidence and impact of thromboembolic events in lung cancer patients treated with nivolumab. J Clin Oncol 2017; 35 (15) e20624-e20624
    CrossrefPubMedGoogle Scholar
  • 71 Khorana AA, Palaia J, Rosenblatt L. et al. Venous thromboembolism incidence and risk factors associated with immune checkpoint inhibitors among patients with advanced non-small cell lung cancer. J Immunother Cancer 2023; 11 (01) e006072
    CrossrefPubMedGoogle Scholar
  • 72 Yuk J-S, Lee B, Kim K. et al. Incidence and risk of venous thromboembolism according to primary treatment type in women with endometrial cancer: a population-based study. BMC Cancer 2021; 21 (01) 1166
    CrossrefPubMedGoogle Scholar
  • 73 Thein KZ, Htut TW, Ball S, Swarup S, Sultan A, Oo TH. Venous thromboembolism risk in patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with combined CDK 4/6 inhibitors plus endocrine therapy versus endocrine therapy alone: a systematic review and meta-analysis of randomized controlled trials. Breast Cancer Res Treat 2020; 183 (02) 479-487
    CrossrefPubMedGoogle Scholar
  • 74 Klil-Drori AJ, Yin H, Tagalakis V, Aprikian A, Azoulay L. Androgen deprivation therapy for prostate cancer and the risk of venous thromboembolism. Eur Urol 2016; 70 (01) 56-61
    CrossrefPubMedGoogle Scholar
  • 75 Hu JC, Williams SB, O'Malley AJ, Smith MR, Nguyen PL, Keating NL. Androgen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism. Eur Urol 2012; 61 (06) 1119-1128
    CrossrefPubMedGoogle Scholar
  • 76 Gao S, Ma JJ, Lu C. Venous thromboembolism risk and erythropoiesis-stimulating agents for the treatment of cancer-associated anemia: a meta-analysis. Tumour Biol 2014; 35 (01) 603-613
    CrossrefPubMedGoogle Scholar
  • 77 Sebuhyan M, Crichi B, Abdallah NA. et al. Drug-drug interaction (DDI) with direct oral anticoagulant (DOAC) in patients with cancer. J Med Vasc 2020; 45 (6S): S31-S38
    PubMedGoogle Scholar
  • 78 Skirvin JA, Lichtman SM. Pharmacokinetic considerations of oral chemotherapy in elderly patients with cancer. Drugs Aging 2002; 19 (01) 25-42
    CrossrefPubMedGoogle Scholar
  • 79 Bellesoeur A, Thomas-Schoemann A, Allard M. et al. Pharmacokinetic variability of anticoagulants in patients with cancer-associated thrombosis: Clinical consequences. Crit Rev Oncol Hematol 2018; 129: 102-112
    CrossrefPubMedGoogle Scholar
  • 80 Bigot F, Boudou-Rouquette P, Arrondeau J. et al. Erlotinib pharmacokinetics: a critical parameter influencing acute toxicity in elderly patients over 75 years-old. Invest New Drugs 2017; 35 (02) 242-246
    CrossrefPubMedGoogle Scholar
  • 81 Slaviero KA, Clarke SJ, Rivory LP. Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy. Lancet Oncol 2003; 4 (04) 224-232
    CrossrefPubMedGoogle Scholar
  • 82 Baker SD, van Schaik RH, Rivory LP. et al. Factors affecting cytochrome P-450 3A activity in cancer patients. Clin Cancer Res 2004; 10 (24) 8341-8350
    CrossrefPubMedGoogle Scholar
  • 83 Kopolovic I, Lee AY, Wu C. Management and outcomes of cancer-associated venous thromboembolism in patients with concomitant thrombocytopenia: a retrospective cohort study. Ann Hematol 2015; 94 (02) 329-336
    CrossrefPubMedGoogle Scholar
  • 84 Carney BJ, Wang TF, Ren S. et al; VENUS Network Investigators. Anticoagulation in cancer-associated thromboembolism with thrombocytopenia: a prospective, multicenter cohort study. Blood Adv 2021; 5 (24) 5546-5553
    CrossrefPubMedGoogle Scholar
  • 85 Wang CK, Ho CF, Niu KY. et al. Risk factors for rebleeding and long-term outcomes in patients with head and neck cancer bleeding: a multicenter study. BMC Cancer 2022; 22 (01) 841
    CrossrefPubMedGoogle Scholar
  • 86 Aspberg S, Yu L, Gigante B, Smedby KE, Singer DE. Risk of ischemic stroke and major bleeding in patients with atrial fibrillation and cancer. J Stroke Cerebrovasc Dis 2020; 29 (03) 104560
    CrossrefPubMedGoogle Scholar
  • 87 Ohta H, Miyake T, Shimizu T. et al. The impact of pharmacological thromboprophylaxis and disease-stage on postoperative bleeding following colorectal cancer surgery. World J Surg Oncol 2019; 17 (01) 110
    CrossrefPubMedGoogle Scholar
  • 88 Wang S, Ye Q, Tu J, Song Y. The location, histologic type, and stage of lung cancer are associated with bleeding during endobronchial biopsy. Cancer Manag Res 2018; 10: 1251-1257
    CrossrefPubMedGoogle Scholar
  • 89 Syrigos K, Grapsa D, Sangare R. et al. Prospective assessment of clinical risk factors and biomarkers of hypercoagulability for the identification of patients with lung adenocarcinoma at risk for cancer-associated thrombosis: the observational ROADMAP-CAT Study. Oncologist 2018; 23 (11) 1372-1381
    CrossrefPubMedGoogle Scholar
  • 90 Norris LA, Ward MP, O'Toole SA. et al. A risk score for prediction of venous thromboembolism in gynecologic cancer: the thrombogyn score. Res Pract Thromb Haemost 2020; 4 (05) 848-859
    CrossrefPubMedGoogle Scholar
  • 91 Rupa-Matysek J, Brzeźniakiewicz-Janus K, Gil L, Krasiński Z, Komarnicki M. Evaluation of the ThroLy score for the prediction of venous thromboembolism in newly diagnosed patients treated for lymphoid malignancies in clinical practice. Cancer Med 2018; 7 (07) 2868-2875
    CrossrefPubMedGoogle Scholar
  • 92 Li A, Wu Q, Luo S. et al. Derivation and validation of a risk assessment model for immunomodulatory drug-associated thrombosis among patients with multiple myeloma. J Natl Compr Canc Netw 2019; 17 (07) 840-847
    CrossrefPubMedGoogle Scholar
  • 93 Sanfilippo KM, Luo S, Wang T-F. et al. Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score. Am J Hematol 2019; 94 (11) 1176-1184
    CrossrefPubMedGoogle Scholar
  • 94 Martens KL, da Costa WL, Amos CI. et al. HIGH-2-LOW risk model to predict venous thromboembolism in allogeneic transplant patients after platelet engraftment. Blood Adv 2021; 5 (01) 167-175
    CrossrefPubMedGoogle Scholar
  • 95 Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138 (05) 1093-1100
    CrossrefPubMedGoogle Scholar